Stanford’s Dr. Kumar and UltraSight are pleased to share new clinical evidence reinforcing UltraSight’s role in scaling access to cardiac ultrasound. 

A newly published randomized controlled trial from Stanford University School of Medicine, led by Dr. Andre Kumar, evaluated how AI-powered cardiac ultrasound guidance accelerates skill acquisition among internal medicine residents with no prior echocardiography experience. The study focused on solving a well-recognized bottleneck in medicine: the limited scalability of expert-level cardiac imaging due to training constraints. 

In this randomized trial, residents used portable ultrasound devices during routine clinical care. Half were equipped with UltraSight’s real-time AI guidance integrated with Philips Lumify, while the control group used standard ultrasound without AI assistance. 

Key outcomes: 

• 43% faster scan acquisition (152 seconds vs. 266 seconds; p<0.001) 
• Higher overall image quality, with RACE scores of 15 vs. 11 (p=0.034) 
• Meaningful proficiency achieved after ~5 scans per user  

Importantly, the performance gains were most pronounced in the most technically-challenging cardiac views – the same views that traditionally limit the scalability of cardiac ultrasound programs. 

Traditional POCUS education typically requires 20–30 supervised scans, often with 1:1 expert mentorship. In this study, UltraSight enabled residents to reach clinically meaningful proficiency with a fraction of the time and oversight, directly addressing the structural training gap facing healthcare systems. 

This marks the second study demonstrating UltraSight’s ability to improve both the speed and quality of cardiac ultrasound acquisition. The technology does not replace experts – it extends their reach into settings where supervision is limited or unavailable.  

With ultrasound demand increasing 55% and training capacity up only 23%, the healthcare system faces a widening structural gap. Technologies that scale expertise without scaling headcount represent a significant, long-term market opportunity. This study represents not only a scientific milestone, but also our broader roadmap of generating rigorous, randomized clinical evidence to support scalable adoption across diverse clinical environments. 

We are grateful for Dr. Kumar’s leadership and Stanford’s collaboration in advancing research that tackles real barriers to care delivery. 

You can access the full peer-reviewed publication here. You can also view Dr. Kumar’s independent commentary here.